Literature DB >> 26412350

Biology before Anatomy in Early Breast Cancer--Precisely the Point.

Clifford A Hudis1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26412350     DOI： 10.1056/NEJMe1512092

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  17 in total

1.  Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.

Authors:  N Kobayashi; M Hikichi; K Ushimado; A Sugioka; Y Kiriyama; M Kuroda; T Utsumi
Journal:  Clin Transl Oncol       Date:  2017-04-13       Impact factor: 3.405

2.  The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.

Authors:  Gulisa Turashvili; Edi Brogi; Monica Morrow; Clifford Hudis; Maura Dickler; Larry Norton; Hannah Y Wen
Journal:  Breast Cancer Res Treat       Date:  2017-06-03       Impact factor: 4.872

3.  Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.

Authors:  Hannah Y Wen; Melissa Krystel-Whittemore; Sujata Patil; Fresia Pareja; Zenica L Bowser; Maura N Dickler; Larry Norton; Monica Morrow; Clifford A Hudis; Edi Brogi
Journal:  Cancer       Date:  2016-08-15       Impact factor: 6.860

4.  Screening for reducing morbidity and mortality in malignant melanoma.

Authors:  Minna Johansson; John Brodersen; Peter C Gøtzsche; Karsten Juhl Jørgensen
Journal:  Cochrane Database Syst Rev       Date:  2019-06-03

5.  21-gene recurrence assay in patients receiving intraoperative radiotherapy: are "favorable" characteristics a surrogate for low recurrence?

Authors:  Bridget A Oppong; Surupa Sen Gupta; Monique Gary; Patricia Wehner; Mihriye Mete; Danjing Zhao; Sulakshana Seevaratnam; Sonali Rudra; Shawna C Willey
Journal:  Gland Surg       Date:  2017-12

6.  The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients.

Authors:  Steven J Katz; Timothy P Hofer; Yun Li; Allison W Kurian; Irina Bondarenko; Jeremy M G Taylor; Reshma Jagsi; Kevin C Ward; Ann S Hamilton
Journal:  Breast Cancer Res Treat       Date:  2016-12-23       Impact factor: 4.624

7.  Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.

Authors:  Christopher R Friese; Yun Li; Irina Bondarenko; Timothy P Hofer; Kevin C Ward; Ann S Hamilton; Dennis Deapen; Allison W Kurian; Steven J Katz
Journal:  Cancer       Date:  2016-10-24       Impact factor: 6.921

8.  Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer.

Authors:  Yanlin Wu; Qiping Meng; Zhixue Yang; Lili Shi; Rongkuan Hu; Peizhuo Zhang; Jinrong Wei; Jie Ren; Bingjing Leng; Dong Xu; Guo-Qin Jiang
Journal:  Oncol Lett       Date:  2018-07-05       Impact factor: 2.967

9.  Clinical implication of subcategorizing T2 category into T2a and T2b in TNM staging of breast cancer.

Authors:  Jiwoong Jung; Young Jin Suh; Byung Kyun Ko; Eun Sook Lee; Eun-Kyu Kim; Nam Sun Paik; Kyung Do Byun; Ki-Tae Hwang
Journal:  Cancer Med       Date:  2018-10-12       Impact factor: 4.452

10.  The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin.

Authors:  Dinesh Chandra Doval; Anurag Mehta; S P Somashekhar; Aparna Gunda; Gurpreet Singh; Amanjit Bal; Siddhant Khare; Chandra Prakash V Serkad; Manjula Adinarayan; Naveen Krishnamoorthy; Devanhalli Govinda Vijay; Radha Anantakrishnan; G S Bhattacharyya; Manjiri M Bakre
Journal:  Breast       Date:  2021-05-28       Impact factor: 4.380
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.